afety of intravitreal high-doe reinjection of triamcinolone acetonide

Purpoe To report ide effect after intravitreal high-doe reinjection of triamcinolone acetonide. Deign Clinical interventional cae erie. Method Forty-ix patient (47 eye) received at leat two intravitreal injection of approximately 20 to 25 mg triamcinolone acetonide for treatment of diabetic macular edema (n = 6 eye), exudative age-related macular degeneration (n = 23), and other dieae. Interval between injection were 6.7 ± 3.4 month, 8.0 ± 4.6 month, and 10.2 month, repectively, before the econd (n = 47 eye), third (n = 9), and fourth (n = 2) injection. Mean follow-up wa 20.7 ± 8.9 month. Reult After no reinjection were complication detected, other than thoe known to occur after a ingle intravitreal injection. After the firt, econd, and third injection, repectively, intraocular preure remained normal in 24 (51%), 25 (53%), and 5 (56%) eye. Concluion Intravitreal high-doage reinjection of triamcinolone acetonide may be tolerated within a mean follow-up of approximately 21 month.